Language:

Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study

Diabetes, Obesity and Metabolism, 2021-01, Vol.23 (1), p.263

2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ;2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com ;EISSN: 1463-1326 ;DOI: 10.1111/dom.14203 ;PMID: 32991065

Digital Resources/Online E-Resources

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study
Author: Sainsbury, Christopher ; Wang, Jingya ; Gokhale, Krishna ; Acosta-Mena, Dionisio ; Dhalla, Samir ; Byne, Nathan ; Chandan, Joht Singh ; Anand, Astha ; Cooper, Jennifer ; Okoth, Kelvin ; Subramanian, Anuradhaa ; Bangash, Mansoor N ; Taverner, Thomas ; Hanif, Wasim ; Ghosh, Sandip ; Narendran, Parth ; Cheng, Kar K ; Marshall, Tom ; Gkoutos, Georgios ; Toulis, Konstantinos ; Thomas, Neil ; Tahrani, Abd ; Adderley, Nicola J ; Haroon, Shamil ; Nirantharakumar, Krishnarajah
Subjects: Aged ; COVID-19 - epidemiology ; Diabetes Mellitus, Type 2 - drug therapy ; Disease Susceptibility ; Female ; Humans ; Male ; Middle Aged ; Pandemics ; Propensity Score ; Retrospective Studies ; SARS-CoV-2 ; Sodium-Glucose Transporter 2 Inhibitors - adverse effects ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Is Part Of: Diabetes, Obesity and Metabolism, 2021-01, Vol.23 (1), p.263
Description: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is associated with COVID-19, when compared with an active comparator. We performed a propensity-score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2 inhibitors (n = 9948) and a comparator group prescribed dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 14 917) were followed up from January 30 to July 27, 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2 inhibitors and 24.7/1000 person-years among propensity-score-matched users of DPP-4 inhibitors. The adjusted hazard ratio was 0.92 (95% confidence interval 0.66 to 1.29), and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2 inhibitors compared to DPP-4 inhibitors, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.
Publisher: England: John Wiley & Sons, Inc
Language: English
Identifier: EISSN: 1463-1326
DOI: 10.1111/dom.14203
PMID: 32991065
Source: Coronavirus Research Database

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study

Searching Remote Databases, Please Wait